Active Biotech AB (publ) filed its Annual on Apr 26, 2023 for the period ending Dec 31, 2022. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.505 SEK | -2.70% |
|
+1.00% | +10.62% |
Jul. 01 | Active Biotech Enters Agreement for A Clinical Study of Tasquinimod in Myelofibrosis | CI |
May. 22 | Active Biotech Secures Exclusive Licensing Rights to Multiple Myeloma Drug | MT |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+10.62% | 17.91M | |
+20.12% | 127B | |
+25.25% | 117B | |
+25.56% | 27.77B | |
-19.51% | 20.44B | |
-14.36% | 16.62B | |
-15.63% | 15.92B | |
-46.67% | 14.94B | |
+11.89% | 14.74B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- ACTI Stock
- News Active Biotech AB
- Active Biotech AB Auditor Raises 'Going Concern' Doubt